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Background: Glomerular filtration rate (GFR) is the gold standard in assessing renal
function but is impractical. Serum creatinine (sCr) has limited sensitivity in identifying
early chronic kidney disease (CKD), whereas symmetric dimethylarginine (SDMA) has
been commercialized as more accurate biomarker. Studies comparing SDMA and sCr
with GFR in cats are limited.
Objectives: To further investigate the diagnostic performance of SDMA in non-
azotemic and azotemic cats.
Animals: Forty-nine client-owned cats: 17 cats with CKD, 15 cats with diabetes
mellitus (DM), and 17 healthy cats.
Methods: Retrospective study using spare blood samples from cats with documented
sCr and GFR results for SDMA analysis. Diagnostic performances of SDMA and sCr
were evaluated using correlation coefficients, sensitivities, specificities, and receiver
operator characteristic curves.
Results: Compared to healthy cats and cats with DM, CKD cats had significantly
higher SDMAplasma (26.7 ± 9.9 μg/dL) and sCr (249.7 ± 71.6 μmol/L [2.8 ± 0.8 mg/dL];
both P < .001) values. SDMAplasma (τB = −0.57; P < .001) and sCr (τB = −0.56;
P < .001) were significantly correlated with GFR. SDMAplasma (τB = 0.52; P < .001)
had a significant relationship with sCr. SDMAplasma and sCr had similar sensitivity
(76%-94% and 71%-88%, respectively) in detecting reduced renal function. Creati-
nine had higher specificity (94%-96%) than SDMAplasma (75%-76%) (P < .05).
Conclusion and Clinical Importance: In this study of azotemic and nonazotemic cats,
SDMA was a reliable marker to identify decreased GFR. However, superiority of
SDMA over sCr could not be confirmed.
Abbreviations: AUC, area under the curve; CKD, chronic kidney disease; DM, diabetes mellitus; GFR, glomerular filtration rate; IRIS, International Renal Interest Society; LC-MS, liquid
chromatography-mass spectrometry; RI, reference interval; ROC, receiver operator characteristic; sCr, serum creatinine; SDMA, symmetric dimethylarginine; USG, urine-specific gravity.
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1 | INTRODUCTION
Chronic kidney disease (CKD) is characterized by loss of structure and
function of 1 or both kidneys over a time span of 3 months or longer.1
Between 1.6% and 20% of all cats develop CKD and the disease
mostly affects elderly cats, the prevalence of CKD reaching up to 80%
in the population of geriatric cats.2-4 It is hoped that early treatment
will delay the natural progressive course of the disease, making early
diagnosis important and regular health screening of senior
(11-14 years) and geriatric (≥15 years) cats essential.5-7
Assessing early renal function loss by measuring glomerular filtration
rate (GFR) is the gold standard but is impractical.8 Chronic kidney disease is
routinely diagnosed using a combination of thorough physical examination,
extensive laboratory testing (including complete blood counts, serum bio-
chemistry profile, and urinalyses), diagnostic imaging, and blood pressure
measurement. Compatible clinical signs, persistent azotemia, and decreased
urine concentrating ability (urine-specific gravity [USG] < 1.035) indicate
onset of azotemic CKD.6 Presence of renal azotemia reflects irreversible
loss of 50% to 75% of functional nephrons, correlating to 50% to 60%
decrease in kidney function.9,10 This discrepancy is attributable to compen-
satory hyperfiltration of remaining nephrons. With the goal of maintaining
the homeostasis, reduction of nephron mass leads to increase in perfusion
and filtration of surviving nephrons. In the short term, the compensatory
hyperfiltration is beneficial as the GFR is partly maintained, but in the long
term this might be detrimental as it promotes intraglomerular hypertension
and ultimately progression of CKD.11 Although GFR decline can already be
substantial in early stages of CKD, serum creatinine (sCr) will not necessar-
ily exceed the upper limit of the reference interval (RI).12 Additionally,
extra-renal factors may interfere with the results of routine biomarkers, sCr
being influenced by diet, age, sex, and muscle mass.13-15 Moreover, sCr has
high interindividual variability, hence the RI is usually wide.16 A conse-
quence of the high interindividual variability is that sCr is not a sensitive
biomarker to identify early CKD using population-based RI.16 These limita-
tions create an urgent need for sensitive markers to identify impaired renal
function before azotemia arises.
Symmetric dimethylarginine (SDMA) is a by-product of protein
methylation that enters the circulation after proteolysis.13 Its excre-
tion is mainly renal (>90%), via glomerular filtration and active secre-
tion.17 Tubular reabsorption is absent.14 In small animals, SDMA is not
affected by muscle mass18,19 or sex,18 creating an advantage over sCr.
It has been claimed that SDMA has superior sensitivity to detect renal
dysfunction compared to sCr. This is mainly based on a retrospective
study containing 42 CKD and healthy geriatric cats in which SDMA
(cut-off 14 μg/dL) showed a higher sensitivity than sCr (cut-off value
185 μmol/L [2.1 mg/dL]) to identify a >30% decrease in GFR.20 The
correlation between SDMA and GFR (r = −0.79; P < .001) proved
equivalent to the correlation between sCr and GFR (r = −0.77;
P < .001), indicating that both renal markers are closely related to the
GFR.20 This finding was also confirmed by other studies which
obtained a coefficient of determination between SDMA and GFR
(R2 = 0.82; P < .001), similar to the relationship between sCr and GFR
(R2 = 0.81; P < .001).13
Since research on the diagnostic performance of SDMA in cats is
limited, this study aimed to verify whether SDMA has added value
over sCr to detect impaired GFR. Our first objective was to compare
the strength of the correlation between the biomarkers and GFR. The
second goal was to evaluate sensitivities, specificities, and optimal
cut-off values for SDMA and sCr.
2 | MATERIAL AND METHODS
2.1 | Study sample and design
This retrospective study was performed at the Small Animal Depart-
ment of the Faculty of Veterinary Medicine. Frozen blood samples
(−80C) from adult, privately owned cats that had undergone GFR
estimation and general health screening as part of previously publi-
shed prospective studies21,22 were used. The cats had been recruited
in a 5-year period between 2009 and 2014.
Based on the results of an extensive physical examination and
routine laboratory analysis, all animals had been categorized into 1 of
3 predefined groups: CKD, diabetes mellitus (DM), and the healthy
control group. The presence of CKD had been determined by a sCr
value higher than the RI (>161.8 μmol/L [>1.83 mg/dL]) in combina-
tion with USG <1.035 (renal azotemia) together with a compatible his-
tory and associated clinical signs.23 The diagnosis of DM had been
based on the combination of hyperglycemia, glucosuria, increased
serum fructosamine concentration, and representative clinical com-
plaints. Cats within the healthy control group did not show any signifi-
cant abnormalities on physical examination, blood examination
(complete blood count, serum biochemistry profile, and total thyrox-
ine concentration), and urinalysis (urinary protein : creatinine ratio and
bacterial culture included).21 These cats were mainly recruited among
staff and students of the faculty of veterinary medicine for participa-
tion in the mentioned prospective research projects.21,22
Signalment data, USG, total thyroxine values, sCr concentration,
and GFR results determined by clearance of exo-iohexol were retro-
spectively retrieved from the medical file of all cats. Symmetric
dimethylarginine concentrations were retrospectively measured in
spare plasma samples. Animals with unknown sCr or exo-iohexol GFR
results and cats with insufficient plasma samples were excluded from
the study. Recently, a nonsignificant relationship was found between
SDMA and GFR in a sample of hyperthyroid cats, possibly because
both production and metabolism of SDMA may be altered due to thy-
roxine changes in the blood, independent of the GFR.24 In the present
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study, hyperthyroidism was diagnosed based on thyroid gland palpa-
tion, compatible clinical signs and a serum total thyroxine concentra-
tion (with RI: 14.19-45.15 nmol/L and measured in the majority of the
study cats). Hyperthyroid cats were excluded from the current study.
2.2 | Analyses
2.2.1 | Glomerular filtration rate
Glomerular filtration rate (GFR) had been measured using a combined
plasma exogenous creatinine Iohexol clearance test (PEC-ICT).21,22,25
Briefly, 64.7 mg/kg exo-iohexol and 40 mg/kg creatinine had been
injected intravenously. Ethylenediaminetetraacetic acid (EDTA) plasma
samples had been collected before and 5, 15, 30, 60, 90, 120, 180, 360,
and 600 minutes after injection. For our study, only values of the exo-
iohexol clearance were used. The plasma levels of exo-iohexol had been
analyzed using high-performance liquid chromatography with ultraviolet
detection.23 Pharmacokinetic analyses had been performed using
WinNonlin (WinNonlin Version 4.0.1, Scientific Consulting Inc, Apex, NC).
The plasma data had been subjected to noncompartmental analysis using
a statistical moment approach. The area under the curve (AUC) of plasma
concentration-vs-time had been calculated using the trapezoidal rule with
extrapolation to infinity, as described by Watson et al.26 Plasma exo-
iohexol clearance had been determined by dividing dose administered by
AUC and indexed to bodyweight (mL/[min kg]).
Evaluation of sensitivity and specificity of indirect markers, SDMA
and sCr, was done by 2 different GFR cut-off values using the same
clearance technique as described by Paepe et al.23 A borderline GFR
cut-off value, indicating mildly impaired renal function, was set at
1.7 mL/(min kg).23 The low GFR cut-off value indicating CKD was set
at 1.2 mL/(min kg).23
2.2.2 | Serum creatinine
The sCr concentration had been determined using a modified Jaffe
method with an RI of 64.5 to 161.8 μmol/L (0.73-1.83 mg/dL).27
2.2.3 | Symmetric dimethylarginine
Residual plasma samples (−80C) from the clearance test were
thawed to 20C and sent in batches to IDEXX Laboratories GmbH,
Leipzig, Germany for analysis. Quantification of SDMA concentration
was performed using the validated immunoassay IDEXX SDMA Test
(IDEXX Laboratories Inc, Westbrook, Maine). The upper limit of the RI
was 14 μg/dL, meaning that values >14 μg/dL were indicative of
impaired renal function. Symmetric dimethylarginine analysis was per-
formed preferably on the basal (T0) sample that was collected just
before the start of the GFR measurement. When plasma samples of
T0 were missing, samples obtained 5 minutes after injection (T5) of
the exo-iohexol marker were used. Storage time of the samples was
at least 3 years and a maximum of 8 years. Plasma samples that
underwent 1 freeze-thaw cycle were only used in cases where there
was no alternative.
2.3 | Statistical analysis
SAS (Statistical Analysis Software Version 9.4, SAS Institute Inc, Cary,
North Carolina) was used for all statistical analyses using a global sig-
nificance level of 5%.
An ANOVA F-test was used to check for the presence of a group
effect on each variable (SDMAplasma, GFR, and sCr) and was followed by
Dunnett's multiple comparisons where diseased animals (DM/CKD) were
compared pairwise with healthy controls. P values were adjusted for mul-
tiple comparisons. Kendall's Tau correlation coefficients (τB) were calcu-
lated to investigate the relationship between GFR and, SDMAplasma, and
sCr. Subsequently, we calculated the specificities and sensitivities (and
95% confidence interval) for SDMAplasma and sCr at their predefined cut-
off values and at 2 different levels of GFR impairment since the renal
clearance is the gold standard for CKD diagnosis. With the 2 different
threshold values for GFR in mind, we calculated sensitivities and specific-
ities corresponding to a wide range of alternative cut-off values of SDMA
and sCr. Sensitivities were plotted against 1-specificities ultimately
resulting in 4 receiver operator characteristic (ROC) curves. For each plot,
the AUC was calculated (with the 95% confidence interval included28) as
an evaluation of the diagnostic accuracy or distinctiveness of the bio-
marker to detect a decreased GFR.
3 | RESULTS
3.1 | Study sample and descriptive statistics
A total of 49 cats were included in this study. Seventeen animals were
diagnosed with CKD. Based on the current International Renal Inter-
est Society (IRIS) guidelines,29 11 had IRIS stage 2 (sCr:
140-250 μmol/L [1.6-2.8 mg/dL]) and 6 had stage 3 CKD (sCr:
251-440 μmol/L [2.9-5.0 mg/dL]). Fifteen cats had DM and 17 cats
were considered healthy control animals. The majority of the animals
with DM were not sufficiently controlled for DM despite therapy, had
fructosamine levels > 600 μmol/L and presence of glucosuria (blood
glucose > 15 mmol/L [270 mg/dL]).
Further characteristics of the study sample are shown in Table 1.
Spare plasma samples were available for all cats. Samples of T0
were missing in 4 cats (all healthy cats), but spare plasma collected at
T5 during the GFR procedure were available for SDMA analysis in
these animals. Five plasma samples underwent 1 freeze-thaw cycle
before SDMA measurement.
As shown in Table 2, a GFR < borderline cut-off value of
1.7 mL/(min kg) was present in 21/49 cats. Sixteen of them belonged
to the CKD group while 2 were diagnosed with DM, and the
remaining 3 cats belonged to the healthy group. Fifteen of these ani-
mals obtained a GFR < the low cut-off value of 1.2 mL/(min kg). One
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of these was recruited as a healthy cat and had sCr of 104 μmol/L and
USG of 1.038. All other cats with a GFR < 1.2 mL/(min kg) belonged
to the CKD group.
Mean results of exo-iohexol GFR, sCr, SDMAplasma, and USG for
the complete study sample and the different subgroups were available
and presented in Table 3. As total thyroxine serum values were miss-
ing in 7/49 cats (subgroup CKD: n = 2; DM: n = 3; control: n = 3),
mean values were calculated based on the available results.
SDMAplasma, sCr, and GFR differed significantly among the groups
(P < .001 for each variable). Cats with CKD possessed significantly
lower GFR results and significantly higher sCr and SDMA concentra-
tions compared to healthy individuals (all P < .001). No significant dif-
ferences in GFR, sCr, and SDMA were found between DM and
healthy animals.
3.2 | Correlation between kidney function tests
Kendall's Tau correlation coefficients (τB) revealed for the 49 cats that
the correlation between SDMAplasma and GFR (τB = −0.57; P < .001)
was moderate; however, the correlation between sCr and GFR was of
the same magnitude (τB = −0.56; P < .001). High concentrations of
both biomarkers were associated with reduced filtration rate. The cor-
relation between the 2 renal biomarkers SDMAplasma and sCr was also
moderate (τB = 0.52; P < .001).
3.3 | Relationship between SDMA and sCr
SDMAplasma and sCr concentrations of the 49 animals were plotted
against each other in Figure 1. Concordant results between both renal
biomarkers were confirmed in 39/49 cats. 24/49 had SDMA and sCr
results within RI in quadrant I and 15/49 had SDMA and sCr results
above the upper reference limit in quadrant IV. Discordant results were
present in 10 animals. Five healthy control cats and 3 DM cats had nor-
mal sCr concentrations but increased SDMA values (quadrant II). How-
ever, 6 of them had a normal GFR (>1.7 mL/[min kg]). Within reference
SDMAplasma and increased sCr levels were represented in quadrant III and
contained 2 cats that were earlier assigned to the CKD group. The first
cat had a GFR measurement <1.7 mL/(min kg), while the renal clearance
of the second was <1.2 mL/(min kg), which indicated that in this cat
SDMA obviously failed to identify CKD in contrast to sCr.
3.4 | Diagnostic value of sCr and SDMA as renal
biomarkers
Sensitivities and specificities for SDMAplasma and sCr to detect GFR
exceeding the borderline (1.7 mL/[min kg]) and low (1.2 mL/[min kg])
GFR cut-off values are shown in Table 4.
We determined the threshold concentrations for SDMA and sCr
that resulted in the ideal combination of sensitivity and specificity to
optimize the diagnostic force for both biomarkers. To identify any cat
with a GFR result <1.7 mL/(min kg), a SDMA cut-off value of 18 μg/
dL and sCr threshold value of 155.6 μmol/L (1.76 mg/dL) was more
TABLE 1 Overview of the different breeds and sexes within the CKD group, DM, and healthy control group presented in absolute numbers
and (percentage ratio between brackets)21,22
CKD n = 17 DM n = 15 Control n = 17 Total n = 49
Breed Eur SH n = 11 (65%) n = 12 (80%) n = 17 (100%) n = 40 (82%)
Other breeds British SH n = 2
Siamese n = 1
Persian n = 1
Ragdoll n = 1
Burmese n = 1
Eastern SH n = 1
British SH n = 1
Burmese n = 1
British SH n = 3
Burmese n = 2
Persian n = 1
Ragdoll n = 1
Siamese n = 1
Eastern SH n = 1
Sex M n = 0 n = 1 (6.5%) n = 0 n = 1 (2%)
F n = 1 (6%) n = 1 (6.5%) n = 0 n = 2 (45%)
Mc n = 10 (59%) n = 12 (80%) n = 5 (29.5%) n = 27 (55%)
Fc n = 6 (35%) n = 1 (6.5%) n = 12 (70.5%) n = 19 (39%)
Abbreviations: British SH, British Shorthair; CKD, chronic kidney disease; DM, diabetes mellitus; Eastern SH, Eastern Shorthair; Eur SH, European
Shorthair; F, female; FC, female castrated; M, male; MC, male castrated.
TABLE 2 Classification of the cat sample of 49 cats based on
estimation of the GFR by exo-iohexol clearance test
Group
GFR (mL/[min kg])
<1.2 1.2 ≤GFR < 1.7 ≥1.7
Chronic kidney disease 15 1 1
Diabetes mellitus 0 2 13
Healthy 1 2 14
Total 16 5 28
Note: Within each group (CKD, DM, and healthy control group), the
number of cats with a normal renal clearance (GFR ≥ 1.7 mL/[min kg]),
mild renal impairment (GFR ≥ 1.2 mL/[min kg] and <1.7 mL/[min kg]), and
severe renal dysfunction (GFR < 1.2 mL/[min kg]) are displayed.
Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; GFR,
glomerular filtration rate.
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appropriate. The associated sensitivities and specificities are also pres-
ented in Table 4.
Receiver operating characteristic curves (Figure 2) illustrate that
the AUC of SDMAplasma and sCr was 0.86 (95% CI = 0.79-0.93) and
0.90 (95% CI = 0.84-0.96), respectively, to detect mild kidney
dysfunction (GFR < borderline GFR cut-off of 1.7 mL/[min kg]). To
detect obvious kidney dysfunction (GFR < low GFR cut-off of
1.2 mL/[min kg]), SDMAplasma had an AUC of 0.95
(95% CI = 0.91-0.99) while sCr achieved an AUC of 0.93
(95% CI = 0.89-0.98) (Figure 3).
F IGURE 1 Scatter plot illustrating the relationship between SDMA (on the x-axis) and sCr (on the y-axis) concentrations measured in
17 healthy animals, 17 CKD cats, and 15 cats with DM. Chronic kidney disease animals are visualized as blue triangles; DM and control cats
obtain the green circle and orange rhombus shape, respectively. Horizontal and vertical lines refer to the threshold values of sCr (161.8 μmol/L
[1.83 mg/dL]) and SDMA (14 μg/dL), respectively. Quadrant I and IV represent the cats with concordant results between SDMA and sCr.
Quadrant II represents the cats with increased SDMA and normal sCr values. Quadrant III represents the cats with normal SDMA and increased
sCr values. The graph demonstrates the positive relationship between both kidney markers (τB = 0.52; P < .001). CKD, chronic kidney disease;
DM, diabetes mellitus; sCr, serum creatinine; SDMA, symmetric dimethylarginine
TABLE 3 Overview of the mean
values and (SDs between brackets) for
GFR, sCr, SDMAplasma, USG, bodyweight
and age for 17 CKD cats, 15 DM cats, 17
healthy cats, and the complete study
sample of 49 cats21,22
CKD n = 17 DM n = 15 Control n = 17 Total n = 49










c 12 (2.4) 12.5 (4.6)c 17.3 (9.5)
USG 1.020 (0.009) 1.036 (0.010) 1.045 (0.009) 1.033 (0.014)
TT4 24.3 (10.1) 14.7 (8.2) 30.2 (6.3) 23.7 (10.3)
Bodyweight 4.2 (1.2) 4.9 (1.2) 4.5 (1.3) 4.5 (1.2)
Age 10.3 (4.9) 9.5 (2.9) 10.5 (3.1) 10.1 (3.7)
Note: Mean values and (SDs between brackets) for TT4 were available for 15 CKD cats, 12 DM cats, 15
healthy cats, and a total of 42 study cats.21,22 GFR in mL/(min kg), sCr in μmol/L and [mg/dL],
SDMAplasma in μg/dL, TT4 in nmol/L, bodyweight in kg, and age in years were available for the 49 cats.
Means sharing the same letter differed significantly from each other (P < .05).
Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; GFR, glomerular filtration rate; sCr,
serum creatinine; SDMA, symmetric dimethylarginine; TT4, total thyroxine; USG, urine-specific gravity.
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4 | DISCUSSION
The present study aimed to investigate the benefit of SDMA as an
indirect renal biomarker in 49 nonazotemic and azotemic cats. By
using an exo-iohexol clearance test, renal function was objectively
established and diagnostic results of SDMA and sCr were evaluated in
light of this gold standard. Using retrospective plasma samples, we
recognized that both biomarkers were equally correlated with the
GFR and we confirmed a mild and clinically nonrelevant difference in
sensitivity between SDMA and sCr in the detection of renal function
loss. In conclusion, the diagnostic results of both tests were
comparable.
Unlike sCr, SDMA is only slightly subjected to extra renal influ-
ence.18,19 Based on the claim that SDMA has superior sensitivity than
sCr to detect real dysfunction, a stronger correlation between SDMA
and GFR compared to the correlation between sCr and GFR could be
anticipated. In contrast, we observed both SDMAplasma and sCr were
equally correlated with the renal clearance. Both biomarkers are wor-
thy as a surrogate marker for GFR measurement to objectively evalu-
ate renal function. Plasma SDMA increased with decreasing renal
clearance but both variables were not perfectly correlated. Variations
in SDMA results cannot be completely attributed to changes in the fil-
tration capacity of the kidney and additional factors in the metabolism
or elimination of the SDMA molecule must be considered.
Until now, the influence of systemic conditions or treatment on
SDMA concentration has been poorly studied in small animals.30
Recent research with hyperthyroid cats showed a poor correlation
between SDMA and GFR values, probably due to changes in protein
metabolism by the hyperthyroid state of the cats.24 Therefore, we
excluded hyperthyroidism based on a number of diagnostic tools
TABLE 4 Sensitivity and specificity for SDMA and sCr with upper reference limits 14 μg/dL and 161.8 μmol/L (1.83 mg/dL), respectively, and
upper reference limits 18 μg/dL and 155.6 μmol/L (1.76 mg/dL), respectively
Cut-off GFR 1.7 mL/(min kg) Cut-off GFR 1.2 mL/(min kg)
Cut-off Sensitivity Specificity Sensitivity Specificity
SDMAplasma 14 μg/dL 76.2 (52.8-91.8) 75 (55.1-89.3) 93.7 (69.8-99.8) 75.7 (57.7-88.9)
18 μg/dL 71.4 (47.8-88.7) 96.4 (81.6-99.9) 87.5 (61.6-98.5) 93.9 (79.8-99.3)
sCr 161.8 μmol/L (1.83 mg/dL) 71.4 (47.8-88.7) 96.4(81.6-99.9) 87.5 (61.7-98.4) 93.9 (79.8-99.3)
155.6 μmol/L (1.76 mg/dL) 76.2 (52.8-91.8) 92.9 (76.5-99.1) 93.8 (69.8-99.8) 90.9 (75.7-98.1)
Note: 95% CIs are added between the brackets. Test positive and negative results are objectively evaluated by means of exceeding the borderline GFR cut-
off and the low GFR cut-off.
Abbreviations: GFR, glomerular filtration rate; sCr, serum creatinine; SDMA, symmetric dimethylarginine.
F IGURE 2 Receiver operator characteristic curves of SDMA (left) and sCr (right) showing the diagnostic ability of the biomarkers to detect
GFR < borderline GFR cut-off (1.7 mL/[min kg]). On the x-axis, 1-specificity is shown for a range of possible cut-off values. The y-axis
demonstrates the sensitivity of the renal biomarker for a range of possible cut-off values. The figure demonstrates a similar AUC of 0.86 (with a
95% CI of 0.79-0.93) and 0.90 (with a 95% CI of 0.84-0.96) for SDMAplasma and sCr, respectively. AUC, area under the curve; GFR, glomerular
filtration rate; sCr, serum creatinine; SDMA, symmetric dimethylarginine
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including the determination of serum total thyroxine. For a limited
number of cats, thyroxine values were missing but based on their
young age, the absence of compatible clinical signs, and a normal thy-
roid palpation; hyperthyroidism was an unlikely diagnosis. In the pre-
sent study, a large number of animals with normal GFR suffered from
DM so an extra-renal influence of this endocrine disorder on plasma
SDMA could not be ruled out. Nevertheless, we could not prove sig-
nificant difference in SDMA blood concentration between the healthy
control group and nonazotemic cats with DM. The influence of (insuf-
ficiently controlled) DM on SDMA concentration with significantly
lower SDMA blood levels in DM cats (without comorbidities) com-
pared to healthy control animals has been reported, probably due to
hyperfiltration and osmotic diuresis.31 Since GFR was not measured in
that study, these findings are hard to interpret. Further investigation
to determine if DM can influence SDMA concentrations in cats is
warranted.
The scatter plot illustrating all SDMA and sCr results indicated
several discordant results. The GFR values indicated that the majority
of cats with conflictingly high SDMA and normal sCr concentrations
showed a false positive SDMA result, reflected in a somewhat lower
specificity of SDMA (76%) compared to SCr (94%-96%). Using the
upper limit of the RI (161.8 μmol/L [1.83 mg/dL] for sCr and 14 μg/dL
for SDMA), sCr only generated a minimum number of false positive
test results (n = 1) while SDMA incorrectly suspected more healthy
cats with deteriorated kidney function (n = 7). As expected, sensitivity
and specificity of both kidney biomarkers was partly influenced by the
GFR cut-off value. The borderline GFR cut-off value generally led to
fewer false positive test results for SDMA and sCr compared to the
low GFR cut-off value. Increased sCr despite normal SDMA results
was recorded in 2 cats. Both cats had a decreased GFR value indicat-
ing false negative SDMA results. However, the perceived differences
in sensitivity between sCr and SDMA in the present study were not
clinically relevant. Both SDMA and sCr correctly identified cats in
advanced stages of renal function loss (<1.2 mL/[min kg]). Overall, it is
important to note that the mild differences in sensitivity and specific-
ity of sCr and SDMA are probably attributable to their RI as both bio-
markers show equal performance in the ROC curve analysis.
According to our data, SDMA offered little added diagnostic value
compared to the long-implemented sCr. The accuracy in detecting a
GFR < 1.7 mL/(min kg) and a GFR < 1.2 mL/(min kg) was investigated,
and diagnostic performance of both markers improved as renal impair-
ment progressed. However, SDMA is commercially promoted as a
highly sensitive diagnostic tool providing extra value in detecting cats
with early renal function loss who are missed with the use of the tra-
ditional renal marker sCr.10,32
Our findings are not completely in line with previous research
due to multiple reasons. Across studies the SDMA cut-off value stays
fixed, but the sCr RI widely varies due to interlaboratory differences
in samples selected for the establishment of the RI. This affects sensi-
tivity of sCr. The higher the upper reference limit, the more false neg-
ative test results are generated which will ultimately result in a lower
sensitivity for this biomarker. Our RI of sCr was determined by Ghys
et al27 and had the important advantage of being laboratory-specific,
but compared to other studies, the upper reference limit for sCr was
rather low. In addition, analytical variation can arise by the usage of
different laboratory quantification techniques for measuring sCr
(enzymatic vs colorimetric) as well as GFR (marker and sampling strat-
egy). This makes comparison between studies challenging. The cross-
F IGURE 3 Receiver operator characteristic curves of SDMA (left) and sCr (right) showing the diagnostic ability of the biomarkers to detect
GFR < low GFR cut-off (1.2 mL/[min kg]). On the x-axis, 1-specificity is shown for a range of possible cut-off values. The y-axis demonstrates the
sensitivity of the renal biomarker for a range of possible cut-off values. The figure demonstrates a similar AUC of 0.95 (with a 95% CI of
0.91-0.99) and 0.93 (with a 95%CI of 0.89-0.98) for SDMAplasma and sCr, respectively. AUC, area under the curve; GFR, glomerular filtration rate;
sCr, serum creatinine; SDMA, symmetric dimethylarginine
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sectional retrospective nature of our research did not allow us to
follow-up the animals over time. This led us to the additional disad-
vantage that we did not possess sufficient data of cats going through
IRIS stage I before the presence of azotemia so it was not possible to
assess the biomarkers for this purpose.
Using ROC curves, we evaluated the threshold values for SDMA
(14 μg/dL) and sCr (161.8 μmol/L [1.83 mg/dL]), which were not ideal
for our data set containing CKD and non-CKD cats. A cut-off for
SDMA yielding a more optimal combination of sensitivity and specific-
ity was 18 μg/dL. Symmetric dimethylarginine with the predetermined
cut-off 14 μg/dL generated many false positives. Since sensitivity and
specificity are strongly intertwined, a cut-off of 18 μg/dL inherently
led to a slight loss in sensitivity, but this disadvantage was limited and
in favor of a higher specificity. After the CKD diagnosis is confirmed
in a clinically stable, hydrated animal (with exclusion of pre- or pos-
trenal problems), recently updated IRIS guidelines allow staging of the
chronic disease by at least 2 measurements of SDMA and sCr in a
fasted animal. Symmetric dimethylarginine repeatedly exceeding
18 μg/dL (even in combination with normal sCr levels) suggests that
the animal suffers from at least CKD stage 2.29 Since our study did
not include serial monitoring of SDMA and sCr, a direct comparison of
our results with the IRIS staging system is not indicated.
For sCr, a slightly lower threshold value of 155.6 μmol/L
(1.76 mg/dL) was preferred. Since the specificity of sCr was high in
our study sample of cats, it was desirable to improve sensitivity to the
disadvantage of a minor loss in specificity.
4.1 | Limitations
Although the present study is retrospective in nature, the majority of
our data (sCr and GFR) originated from cats recruited in the context
of previous prospective research studies.21,22 All the cats included
were subjected to the same protocol: a general physical examination,
blood and urine testing, and a GFR clearance test. This minimized the
limitations of the retrospective nature of the present study. The most
important inclusion criterion for our study was the availability of suffi-
cient residual blood samples in order to perform SDMA analysis,
implying that the 49 cats were not randomly selected. This was disad-
vantageous in obtaining a representative study sample.
We aimed to test the accuracy of SDMA and sCr in a sample of
nonazotemic and azotemic cats. Performance of a kidney marker is
better with advanced renal failure (IRIS stage III/IV) while the chal-
lenge and added value of a biomarker is mainly based on its capacity
to identify animals with minimal GFR loss.33 Five cats out of all
achieved a renal clearance between 1.2 and 1.7 mL/(min kg), indicat-
ing the presence of mild renal impairment. Furthermore, the small
number of cats with early CKD could explain the reason for no added
diagnostic value of SDMA that could be established in our data set
and further studies are needed.
The allocation of the cats to the different subgroups was based
on physical examination and routine laboratory analysis. But when the
GFR result was taken into account, 3 cats initially considered as
healthy and 2 cats with DM were found to have mildly impaired renal
function. On the other hand, 1 cat of the CKD group had a GFR value
>1.7 mL/(min kg).
Residual frozen blood samples stored for maximum 8 years were
used for SDMA analysis. Short-term stability of the molecule in blood
has already been reported.34 The effect of long-term preservation on
accurate analysis of SDMA is a relevant issue that has not been clari-
fied. In addition, several plasma samples (n = 5) were subjected to
1 freeze-thaw cycle before SDMA analysis. Multiple freeze-thaw
cycles do not generate significant changes in the SDMA concentra-
tion.34 Furthermore, IDEXX claims the molecule remains stable for
several years if the sample is frozen.30
Symmetric dimethylarginine concentrations were quantified using
the immunoassay “SDMA IDEXX test” and not the gold standard liq-
uid chromatography-mass spectrometry (LC-MS). The SDMA IDEXX
test uses glucose-6-phosphate dehydrogenase conjugate and mono-
clonal anti-SDMA antibodies, is less expensive and time-consuming
than the LC-MS, and is currently widely used in commercial veterinary
laboratories. This means that the results of our study have the advan-
tage of being clinically applicable to veterinary practice. The IDEXX
SDMA test is an accurate technique. Within the 10 to 45 μg/dL range,
the maximum measurement error is estimated to be 1 to 3 μg/dL.35 In
addition, the test is not sensitive to lipemia, icterus, or mild-to-
moderate hemolysis, which usually arises during blood sampling.32
5 | CONCLUSIONS
In this retrospective study, SDMA behaved as an accurate biomarker
for detecting impaired renal function defined by exo-iohexol clearance
in cats. However, in the present sample of adult nonazotemic and azo-
temic cats, we could not prove that SDMA offered prominent added
value compared to the conventional sCr biomarker. The diagnostic
value of both molecules was approximately equivalent and improved
in the advanced phases of renal dysfunction.
ACKNOWLEDGMENT
No funding was received for this study.
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
(IACUC) OR OTHER APPROVAL DECLARATION
Authors declare no IACUC or other approval was needed.
HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.




1. Polzin DJ. Chronic kidney disease in small animals. Vet Clin North Am
Small Anim Pract. 2011;41:15-30.
2. Lund EM, Armstrong PJ, Kirk CA, Kolar LM, Klausner JS. Health status
and population characteristics of dogs and cats examined at private
veterinary practices in the United States. J Am Vet Med Assoc. 1999;
214:1336-1341.
3. Watson ADJ. Indicators of renal insufficiency in dogs and cats pres-
ented at a veterinary teaching hospital. Aust Vet Pract. 2001;31:
54-59.
4. Marino CL, Lascelles BDX, Vaden SL, Gruen ME, Marks SL. Preva-
lence and classification of chronic kidney disease in cats randomly
selected from four age groups and in cats recruited for degenerative
joint disease studies. J Feline Med Surg. 2014;16:465-472.
5. FAB (Feline Advisory Bureau). WellCat for life. A guide to engaging
your clients in a lifelong partnership. Wellcat Veterinary Handbook. 1st
ed. Tisbury, UK: International Cat Care; 2008:1-30.
6. Paepe D, Daminet S, Feline CKD. Diagnosis, staging and screening -
what is recommended? J Feline Med Surg. 2013;15:15-27.
7. Cannon M. Diagnosis and investigation of chronic kidney disease in
cats. In Pract. 2016;38:2-9.
8. Von Hendy-Willson VE, Pressler BM. An overview of glomerular fil-
tration rate testing in dogs and cats. Vet J. 2011;188:156-165.
9. Braun JP, Lefebvre HP, Watson AD. Creatinine in the dog: a review.
Vet Clin Pathol. 2003;32:162-179.
10. Hokamp JA, Nabity MB. Renal biomarkers in domestic species. Vet
Clin Pathol. 2016;45:28-56.
11. Forrester SD, Adams LG, Allen TA. Chronic kidney disease. In:
Hand MS, Thatcher CD, Remillard RL, et al., eds. Small Animal Clinical
Nutrition. 5th ed. Topeka, KS: Mark Morris Institute; 2010:765-810.
12. Lees GE. Early diagnosis of renal disease and renal failure. Vet Clin
North Am Small Anim Pract. 2004;34:867-885.
13. Braff J, Obare E, Yerramilli M, Elliott J, Yerramilli M. Relationship
between serum symmetric dimethylarginine concentration and glo-
merular filtration rate in cats. J Vet Intern Med. 2014;28:1699-1701.
14. El-Khoury JM, Bunch DR, Hu B, et al. Comparison of symmetric
dimethylarginine with creatinine, cystatin C and their eGFR equations
as markers of kidney function. Clin Biochem. 2016;49:1140-1143.
15. Kielstein JT, Fliser D, Veldink H. Asymmetric dimethylarginine and
symmetric dimethylarginine: axis of evil or useful alliance? Semin Dial.
2009;22:346-350.
16. Kopke MA, Burchell RK, Ruaux CG, Burton SE, Lopez-Villalobos N,
Gal A. Variability of symmetric dimethylarginine in apparently healthy
dogs. J Vet Intern Med. 2018;32:736-742.
17. Yerramilli M, Farace G, Quinn J, Yerramilli M. Kidney disease and the
nexus of chronic kidney disease and acute kidney injury: the role of
novel biomarkers as early and accurate diagnostics. Vet Clin North Am
Small Anim Pract. 2016;46:961-993.
18. Hall JA, Yerramilli M, Obare E, Yerramilli M, Yu S, Jewell DE. Compari-
son of serum concentrations of symmetric dimethylarginine and cre-
atinine as kidney function biomarkers in healthy geriatric cats fed
reduced protein foods enriched with fish oil, L-carnitine, and
medium-chain triglycerides. Vet J. 2014;202:588-596.
19. Hall JA, Yerramilli M, Obare E, Yerramilli M, Melendez LD, Jewell DE.
Relationship between lean body mass and serum renal biomarkers in
healthy dogs. J Vet Intern Med. 2015;29:808-814.
20. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. Comparison of
serum concentrations of symmetric dimethylarginine and creatinine
as kidney function biomarkers in cats with chronic kidney disease.
J Vet Intern Med. 2014;28:1676-1683.
21. Paepe D, Ghys LFE, Smets P, Lefebvre HP, Croubels S, Daminet S.
Routine kidney variables, glomerular filtration rate and urinary
cystatin C in cats with diabetes mellitus, cats with chronic kidney dis-
ease and healthy cats. J Feline Med Surg. 2015;17:880-888.
22. Ghys LFE, Paepe D, Lefebvre HP, et al. Evaluation of cystatin C for
the detection of chronic kidney disease in cats. J Vet Intern Med.
2016;30:1074-1082.
23. Paepe D, Lefebvre HP, Concordet D, van Hoek I, Croubels S,
Daminet S. Simplified methods for estimating glomerular filtration
rate in cats and for detection of cats with low or borderline glomeru-
lar filtration rate. J Feline Med Surg. 2015;17:889-900.
24. Buresova E, Stock E, Paepe D, et al. Assessment of symmetric
dimethylarginine as a biomarker of renal function in hyperthyroid cats
treated with radioiodine. J Vet Intern Med. 2019;33:516-522.
25. van Hoek I, Vandermeulen E, Duchateau L, et al. Comparison and
reproducibility of plasma clearance of exogenous creatinine, exo-
iohexol, endo-iohexol, and 51Cr-EDTA in young adult and aged
healthy cats. J Vet Intern Med. 2007;21:950-958.
26. Watson ADJ, Lefebvre HP, Concordet D, et al. Plasma exogenous cre-
atinine clearance test in dogs: comparison with other methods and
proposed limited sampling strategy. J Vet Intern Med. 2002;16:22-23.
27. Ghys LFE, Paepe D, Duchateau L, et al. Biological validation of feline
serum cystatin C: the effect of breed, age and sex and establishment
of a reference interval. Vet J. 2015;204:168-173.
28. NCSS. Confidence Intervals for the Area under an ROC Curve.
https://ncss-wpengine.netdna-ssl.com/wp-content/themes/ncss/
pdf/Procedures/PASS/Confidence_Intervals_for_the_Area_Under_
an_ROC_Curve.pdf. Accessed July 21, 2020.
29. IRIS. Kidney Guidelines - IRIS Staging of CKD (modified 2019). http://
www.iris-kidney.com/guideline/staging.html. Accessed January
12, 2020.
30. IDEXX. SDMA Frequently Asked Questions. https://www.idexx.com/
en/veterinary/reference-laboratories/sdma/sdma-faqs/. Accessed
January 12, 2020.
31. Langhorn R, Kieler IN, Koch J, Christiansen LB, Jessen LR. Symmetric
dimethylarginine in cats with hypertrophic cardiomyopathy and dia-
betes mellitus. J Vet Intern Med. 2018;32:57-63.
32. Relford R, Robertson J, Clements C. Symmetric dimethylarginine:
improving the diagnosis and staging of chronic kidney disease in small
animals. Vet Clin North Am Small Anim Pract. 2016;46:941-960.
33. Pelander L, Häggström J, Larsson A, et al. Comparison of the diagnos-
tic value of symmetric dimethylarginine, cystatin C, and creatinine for
detection of decreased glomerular filtration rate in dogs. J Vet Intern
Med. 2019;33:630-639.
34. Nabity MB, Lees GE, Boggess MM, et al. Symmetric dimethylarginine
assay validation, stability, and evaluation as a marker for the early
detection of chronic kidney disease in dogs. J Vet Intern Med. 2015;
29:1036-1044.
35. Ernst R, Ogeer J, McCrann D, et al. Comparative performance of
IDEXX SDMA test and the DLD SDMA ELISA for the measurement
of SDMA in canine and feline serum. PLoS One. 2018;13:e0205030.
How to cite this article: Brans M, Daminet S, Mortier F,
Duchateau L, Lefebvre HP, Paepe D. Plasma symmetric
dimethylarginine and creatinine concentrations and glomerular
filtration rate in cats with normal and decreased renal
function. J Vet Intern Med. 2021;35:303–311. https://doi.org/
10.1111/jvim.15975
BRANS ET AL. 311
